Reclast, the latest osteoporosis drug that may be coming to market in 2007 will be a once-a-year treatment. Basically, you are given a massive "infusion" in one sitting. These drug companies keep trying to one-up each other. Boniva is trying to one-up Fosamax by putting out a once-a-month pill and now Novartis is going for once-a-year. What's next - once a lifetime? Let's go even further - how about never?
Why doesn't the Washington Post mention that it is a bisphosphonate and will carry the same risks as other bisphosphonates?
Reclast, given as an annual 15-minute infusion, reduced risk of new spine fractures by 70 percent and hip fractures by 40 percent, according to data supplied by the maker, Novartis Pharmaceuticals Corp. The drug, chemically known as zoledronic acid, also reduced the risk of fractures elsewhere, according to a just-completed international study of 7,736 postmenopausal women with osteoporosis.